Asset Details
Do you wish to reserve the book?
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
Do you wish to request the book?
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
2015
Overview
Monoclonal antibodies (MAbs) form a central part of chronic lymphocytic leukaemia (CLL) treatment. We therefore evaluated whether complement defects in CLL patients reduced the induction of complement-dependent cytotoxicity (CDC) by using anti-CD20 MAbs rituximab (RTX) and ofatumumab (OFA). Ofatumumab elicited higher CDC levels than RTX in all CLL samples examined, particularly in poor prognosis cohorts (11q− and 17p−). Serum sample analyses revealed that 38.1% of patients were deficient in one or more complement components, correlating with reduced CDC responses. Although a proportion of patients with deficient complement levels initially induced high levels of CDC, on secondary challenge CDC activity in sera was significantly reduced, compared with that in normal human serum (NHS;
P
<0.01;
n
=52). In addition, a high CLL cell number contributed to rapid complement exhaustion. Supplementing CLL serum with NHS or individual complement components, particularly C2, restored CDC on secondary challenge to NHS levels (
P
<0.0001;
n
=9).
In vivo
studies revealed that complement components were exhausted in CLL patient sera post RTX treatment, correlating with an inability to elicit CDC. Supplementing MAb treatment with fresh-frozen plasma may therefore maintain CDC levels in CLL patients with a complement deficiency or high white blood cell count. This study has important implications for CLL patients receiving anti-CD20 MAb therapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Chronic lymphocytic leukemia
/ Complement deficiency (Immunology)
/ Complement System Proteins - deficiency
/ Complications and side effects
/ Humans
/ Leukemia
/ Leukemia, Lymphocytic, Chronic, B-Cell - blood
/ Leukemia, Lymphocytic, Chronic, B-Cell - therapy
/ Medicine
/ Oncology
/ Toxicity
